share_log

EF Hutton Initiates Coverage On ImmunityBio With Buy Rating, Announces Price Target of $30

Benzinga ·  Oct 23, 2024 19:11  · Ratings

EF Hutton analyst Jason Kolbert initiates coverage on ImmunityBio (NASDAQ:IBRX) with a Buy rating and announces Price Target of $30.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment